Showing results (91-100 of 504) with videos related to
Sort By:
Pageof 51
Urology|June 18, 2005
Partial adrenalectomy: the National Cancer Institute experienceEric K Diner, Michael E Franks, Ashish Behari, et al.The Journal of Urology|May 20, 2008
Feasibility and outcomes of repeat partial nephrectomyAaron Johnson, Sunil Sudarshan, Jack Liu, et al.Proceedings of the National Academy of Sciences of the United States of America|October 24, 2009
Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2Yukiko Hasumi, Masaya Baba, Rieko Ajima, et al.Human Pathology|December 4, 2012
Primary neuroendocrine tumors of the kidney: morphological and molecular alterations of an uncommon malignancyPhyu P Aung, Keith Killian, Carrie O Poropatich, et al.International Journal of Surgical Oncology|February 8, 2012
Familial renal cancer: molecular genetics and surgical managementGlen W Barrisford, Eric A Singer, Inger L Rosner, et al.The Journal of Clinical Endocrinology and Metabolism|March 20, 2023
Germline- and Somatic-Inactivating FLCN Variants in Parathyroid Cancer and Atypical Parathyroid TumorsSmita Jha, James Welch, Rana Tora, et al.The Journal of Pathology|November 3, 2025
mTOR-mediated upregulation of B7-H3 in MiT/TFE translocation renal cell carcinomaHuili Li, Adrianna Amaral, Thiago Vidotto, et al.The Journal of Urology|April 19, 2011
The impact of germline BHD mutation on histological concordance and clinical treatment of patients with bilateral renal masses and known unilateral oncocytomaRonald S Boris, Jihane Benhammou, Maria Merino, et al.Journal of Cancer|April 7, 2012
Targeting the mTOR pathway in Chromophobe Kidney CancerBrian Shuch, Srinivas Vourganti, Julia C Friend, et al.Nature Clinical Practice. Urology|February 14, 2006
Management of von Hippel-Lindau-associated kidney cancerRobert L Grubb, Peter L Choyke, Peter A Pinto, et al.Pageof 51